inhibitor
proteas
pi
design
block
activ
viral
aspartylproteas
howev
accept
famili
inhibitor
also
affect
activ
cell
proteas
sinc
replic
mani
viru
speci
requir
activ
host
cell
proteas
investig
effect
pi
life
cycl
virus
hiv
would
interest
potent
inhibit
induc
saquinavir
nelfinavir
replic
vesicular
stomat
influenza
virus
describ
unrel
envelop
rna
virus
infect
target
cell
upon
endocytosi
intracellular
fusion
piinduc
inhibit
appar
consequ
block
level
fusion
viral
envelop
endosom
membran
find
would
open
way
toward
therapeut
use
pi
envelop
rna
virus
hiv
hiv
proteas
inhibitor
pi
famili
small
molecul
specif
design
block
activ
hiv
aspartylproteas
review
see
flexner
pi
treatment
lead
block
hiv
matur
consequ
releas
noninfecti
viral
particl
kaplan
et
al
pi
exert
inhibitori
effect
disabl
enzym
cleav
gagpol
polyprotein
essenti
product
pi
togeth
antihiv
compound
target
altern
step
viru
life
cycl
part
advanc
antihiv
therapi
allow
million
infect
peopl
coexist
viru
experienc
good
qualiti
life
howev
clear
pi
also
directli
indirectli
inhibit
activ
mani
cell
proteas
particular
pi
inhibit
activ
et
al
pajonk
et
al
proteasom
subunit
well
caspas
badley
alter
suscept
apoptosi
stimuli
express
releas
matrixmetalloproteinas
mmp
also
target
pi
bourlier
et
al
de
barro
et
al
consequ
extracellular
matrix
model
gener
cellcel
commun
addit
pi
found
inhibit
cell
signal
pathway
involv
dewan
et
al
akt
kumar
et
al
srirangam
et
al
clinic
point
view
pi
treatment
may
induc
benefici
effect
hiv
case
kaposi
sarcoma
regress
sgadari
et
al
also
detriment
consequ
dyslipidemia
occur
pitreat
hiv
patient
calza
et
al
enter
target
cell
envelop
rna
virus
fuse
envelop
either
cell
surfac
phindepend
way
upon
intern
intracellular
vesicl
phdepend
mechan
steven
spear
latter
case
low
ph
requir
induc
fusion
viral
envelop
endosom
membran
phenomenon
lead
releas
virion
content
cytoplasm
although
viral
fusion
process
guid
presenc
viral
envelop
protein
contribut
cell
protein
critic
use
rna
interfer
tool
gene
express
inhibit
demonstr
sever
cell
protein
involv
mechan
entri
mani
virus
includ
nguyen
et
al
influenza
hao
et
al
west
nile
krishnan
et
al
borna
diseas
clement
et
al
human
hepat
c
ng
et
al
vesicular
stomat
vsv
pelkman
et
al
virus
ideal
cell
product
might
repres
potenti
antivir
therapeut
target
piinduc
inhibit
replic
vsv
influenza
viru
describ
first
time
like
consequ
pidepend
block
viral
envelop
fusion
endosom
consid
pi
well
toler
drug
vivo
mani
relev
human
pathogen
belong
famili
rna
virus
infect
cell
endocyt
pathway
find
would
open
way
toward
broader
therapeut
use
pi
hiv
virion
emerg
cell
treat
pi
remain
immatur
viral
particl
consequ
block
gag
polyprotein
cleavag
henc
pi
affect
amount
hiv
releas
infect
cell
dramat
decreas
infect
surprisingli
enough
howev
releas
cell
infect
pseudotyp
envelop
protein
vsv
vsvg
found
inhibit
pi
singl
cycl
replic
assay
fact
cem
gfp
cell
ie
human
lymphoblastoid
cell
line
express
gfp
control
ltr
gervaix
et
al
infect
ng
cell
vsvg
decreas
percentag
express
cell
observ
ritonavirtr
cell
compar
control
condit
fig
outcom
chang
challeng
cell
dose
ng
cell
shown
convers
expect
pitreat
appar
effect
singl
cycl
replic
nonpseudotyp
test
pitreat
cultur
cem
gfp
cell
infect
wt
fig
experi
presenc
ie
potent
inhibitor
envmedi
fusion
kilbi
et
al
ad
h
challeng
ensur
wt
replic
limit
singl
cycl
anticip
ritonavir
block
spread
wt
multiplecycl
replic
assay
fig
exclud
observ
effect
consequ
inhibit
yet
unidentifi
function
proteas
earli
step
viru
life
cycl
assay
reproduc
use
vsvg
pseudotyp
piresist
strain
refer
viral
mutant
express
piresist
viral
proteas
consequ
four
amino
acid
substitut
proteas
gene
ie
l
p
v
v
condra
et
al
first
real
resist
pi
check
evalu
percentag
cem
gfp
infect
cell
day
infect
presenc
ritonavir
fig
cem
gfp
cell
treat
infect
vsvg
presenc
ritonavir
experiment
set
repres
singlecycl
replic
assay
sinc
disabl
envmedi
viral
entri
possibl
cell
reinfect
similarli
observ
vsvg
strain
signific
inhibitori
effect
ritonavir
express
detect
vsvg
challeng
cell
fig
strongli
suggest
viral
proteas
activ
involv
piinduc
inhibit
vsvg
express
overal
result
consequ
still
unrecogn
inhibitori
effect
pi
step
viral
entri
driven
vsvg
next
possibl
pi
inhibitori
effect
oper
also
vsv
investig
end
hela
cell
pretreat
overnight
differ
concentr
six
pi
ie
ritonavir
indinavir
saquinavir
nelfinavir
amprenavir
atazanavir
cell
challeng
moi
vsv
h
adsorpt
small
volum
viral
inoculum
remov
cell
extens
wash
incub
addit
h
presenc
pi
afterward
supernat
harvest
titrat
amount
infecti
vsv
depict
fig
strong
reduct
vsv
replic
log
observ
cell
treat
saquinavir
nelfinavir
inhibitori
effect
appear
potent
log
increas
concentr
pi
remain
signific
ie
log
increas
moi
shown
differ
observ
pi
pretreat
carri
h
shown
calcul
wide
doserespons
curv
inhibitori
concentr
ic
valu
saquinavir
nelfinavir
respect
hand
signific
inhibit
viral
replic
detect
ritonavir
indinavir
treat
cell
start
concentr
fig
ic
ritonavir
saquinavir
respect
idea
pi
neg
affect
vsv
replic
strengthen
perform
set
stringent
challeng
experi
detail
hela
cell
pretreat
optim
concentr
effect
pi
infect
decreas
amount
vsv
start
moi
cytopath
effect
monitor
h
post
challeng
outcom
assay
score
term
viral
dilut
abl
induc
cytopath
effect
notabl
condit
reduct
vsv
infect
observ
cell
treat
saquinavir
nelfinavir
fig
sinc
averag
replic
time
vsv
h
whelan
et
al
experiment
set
vsv
expect
complet
least
three
replic
cycl
control
cell
control
whether
antivir
effect
consequ
gener
cytotox
pi
aim
cell
treat
differ
pi
concentr
h
label
carboxyfluorescein
diacet
succinimidyl
ester
cfse
thereaft
refe
complet
medium
presenc
pi
cfse
expect
equal
distribut
upon
cell
divis
result
halv
overal
cell
fluoresc
cell
duplic
cytotox
effect
measur
term
inhibit
cell
duplic
detect
impair
halv
cfseassoci
cell
fluoresc
fig
report
mean
fluoresc
intens
mfi
measur
cell
cultur
treat
differ
concentr
pi
activ
vsv
replic
block
cell
duplic
cell
mortal
detect
use
ritonavir
saquinavir
nelfinavir
indinavir
show
much
lower
cytotox
effect
cytotox
concentr
cc
valu
pi
fig
insert
calcul
dose
inhibit
fluoresc
halv
expectedli
consequ
block
duplic
cell
therapeut
index
ie
cc
divid
ic
appear
higher
saquinavir
nelfinavir
suggest
specif
antivir
effect
pi
taken
togeth
data
reveal
previous
unrecogn
effect
pi
vsv
addit
result
support
idea
piinduc
reduct
vsvg
express
consequ
inhibit
step
viral
entri
involv
vsvg
envelop
protein
add
relev
find
possibl
inhibitori
effect
pi
appli
also
altern
viru
speci
infect
phdepend
fusion
investig
aim
well
character
influenza
virusmdck
cell
system
consid
mdck
cell
treat
overnight
differ
pi
challeng
moi
influenza
viru
challeng
cell
extens
wash
reseed
medium
without
serum
presenc
pi
ethyl
chloromethyl
keton
tpck
treat
trypsin
twentyfour
h
later
ie
expect
time
complet
replic
cycl
influenza
viru
sidorenko
reichl
smith
ribeiro
supernat
harvest
titrat
content
infecti
particl
strong
inhibit
replic
influenza
viru
log
lower
moi
detect
saquinavir
nelfinavir
fig
ritonavir
inhibit
viral
replic
less
effici
fig
indinavir
amprenavir
atazanavir
appear
ineffect
shown
interpret
data
emphas
inhibitori
effect
pi
consequ
piinduc
impair
activ
hemagglutinin
envelop
protein
ha
influenza
viru
step
requir
product
infect
steinhauer
fact
influenza
viru
prepar
use
challeng
exclus
recov
allanto
fluid
embryon
chicken
egg
ha
cleav
egg
proteas
consist
tpcktrypsin
influenc
infect
viru
prepar
singl
cycl
replic
assay
shown
cell
cytotox
pi
activ
influenza
viru
evalu
mdck
cell
similarli
describ
hela
cell
fig
block
cell
duplic
presenc
cell
mortal
detect
ritonavir
saquinavir
nelfinavir
therapeut
index
appear
higher
saquinavir
nelfinavir
assay
gave
similar
result
cell
analyz
h
cfse
label
shown
taken
togeth
data
suggest
pi
could
target
replic
divers
envelop
virus
infect
phdepend
endocyt
pathway
next
investig
whether
pi
effect
vsv
influenza
viru
replic
counteract
also
replic
virus
infect
phindepend
mechan
proof
principl
pi
assay
replic
newcastl
diseas
viru
ndv
ie
paramixoviru
infect
upon
fusion
cell
surfac
mdck
cell
pretreat
saquinavir
nelfinavir
infect
decreas
amount
ndv
start
moi
cytopath
effect
monitor
h
post
challeng
signific
reduct
ndv
infect
notic
pitreat
compar
control
cell
cultur
fig
result
indic
pi
affect
replic
virus
enter
phindepend
way
inhibitori
effect
oper
pi
coadminist
infect
viru
identifi
viru
replic
step
target
pi
effect
pi
ad
andor
viral
challeng
evalu
assay
carri
use
helavsv
mdckinfluenza
viru
system
first
set
experi
pi
treatment
discontinu
viru
challeng
cell
infect
vsv
influenza
viru
moi
respect
h
adsorpt
cell
extens
wash
refe
appropri
medium
condit
inhibit
replic
vsv
influenza
viru
detect
fig
altern
pi
ad
soon
viru
adsorpt
differ
time
challeng
within
timefram
h
vsv
infect
h
case
challeng
influenza
viru
ie
respect
replic
time
supernat
harvest
h
vsv
h
influenza
viru
postinfect
titrat
amount
infecti
viru
particl
appear
pi
inhibit
viru
replic
also
ad
earli
challeng
fig
inhibitori
effect
drop
shortli
case
vsv
infect
gradual
cell
infect
influenza
viru
saquinavir
nelfinavir
shown
similar
inhibitori
effici
shown
result
indic
presenc
pi
earli
time
viru
challeng
mandatori
inhibitori
effect
consist
idea
pi
target
earli
event
replic
cycl
virus
vsv
vsvg
proteas
independ
manner
support
idea
pi
would
influenc
common
earli
replic
step
eg
viru
attach
endocytosi
andor
endosom
fusion
dissect
among
differ
possibl
intracellular
fate
challeng
viru
follow
use
gfplabel
vlp
muratori
et
al
pseudotyp
either
wt
fusiondefect
vsvg
fig
fluoresc
vlp
reli
high
incorpor
level
product
fusion
gfp
nef
mutant
acquir
palmitoyl
site
nterminu
consequ
g
c
substitut
amino
acid
first
possibl
effect
pi
viru
attach
target
cell
investig
end
hela
cell
treat
pi
challeng
ng
wt
vsvg
nef
gfp
vlp
h
afterward
cell
extens
wash
fac
analyz
control
cellassoci
fluoresc
consequ
endocytos
vlp
part
cell
sampl
treat
trypsin
appear
treatment
pi
significantli
affect
cell
bind
fluoresc
vlp
fig
strongli
suggest
pi
interfer
bind
viral
particl
cell
membran
next
influenc
pi
viru
endocytosi
investig
aim
gfpfluoresc
vlp
incorpor
vsvg
mutant
refer
fd
vsvg
unabl
support
phdepend
fusion
use
impair
fusion
activ
consequ
k
amino
acid
substitut
posit
fredericksen
whitt
use
envelop
protein
mutant
associ
trypsin
treatment
fac
analysi
ensur
cellassoci
fluoresc
signal
exclus
refer
intracellular
accumul
vlp
hela
cell
treat
pi
challeng
ng
equival
fd
vsvg
nef
gfp
cell
incub
h
presenc
pi
cell
treat
trypsin
cellassoci
gfp
fluoresc
evalu
fac
analysi
control
vlpchalleng
cell
incub
trypsin
treatment
appar
differ
cellassoci
fluoresc
detect
control
pitreat
cell
fig
suggest
pi
influenc
effici
endocytosi
viral
particl
conclus
enforc
result
obtain
altern
experiment
approach
control
pitreat
hela
cell
infect
pfucel
vsv
thirti
min
later
cell
extens
wash
treat
trypsin
leav
nonadsorb
viral
particl
lyse
analyz
western
blot
presenc
vsvg
signific
reduct
vsvg
specif
signal
detect
time
point
pitreat
cell
compar
control
condit
fig
consid
neosynthesi
vsvg
start
least
min
postinfect
rothman
lodish
result
consist
data
obtain
fluoresc
vlp
suggest
pi
affect
endocytosi
viral
particl
result
experi
indic
inhibitori
effect
pi
consequ
impair
attach
endocytosi
viral
particl
next
possibl
inhibitori
effect
pi
consequ
defect
endosom
cytoplasm
viru
deliveri
investig
end
differ
cellassoci
fluoresc
level
cell
intern
wt
fd
vsvg
pseudotyp
nef
gfp
vlp
exploit
fact
use
experiment
condit
describ
endocytosi
assay
reproduc
observ
earli
vlp
challeng
mean
fluoresc
intens
mfi
cell
challeng
wt
vsvg
vlp
near
higher
cell
treat
fd
vsvg
vlp
significantli
latter
condit
percentag
fluoresc
cell
mfi
heavili
drop
h
challeng
contrari
fac
paramet
appear
slightli
reduc
cell
challeng
wt
vsvg
vlp
fig
differ
explain
fact
due
inabl
fd
vsvg
induc
fusion
deliveri
vlp
content
cytoplasm
nef
gfp
molecul
incorpor
fd
vsvg
vlp
address
rapid
degrad
endosomallysosom
compart
convers
effici
fusion
viral
envelop
endosom
membran
induc
wt
vsvg
allow
releas
nef
gfp
molecul
cytoplasm
expect
degrad
kinet
much
slower
oper
endosomeslysosom
next
pitreat
untreat
hela
cell
challeng
ng
equival
either
wt
vsvg
fd
vsvg
nef
gfp
cell
h
later
cell
treat
trypsin
fac
analysi
cellassoci
gfp
fluoresc
reveal
pi
treatment
affect
fluoresc
level
cell
challeng
fd
vsvg
nef
gfp
vlp
time
point
contrari
h
observ
relev
reduct
mfi
within
pitreat
cell
challeng
wt
vsvg
nef
gfp
vlp
compar
untreat
cell
strikingli
strong
decreas
mfi
percentag
fluoresc
cell
detect
pitreat
cell
h
postchalleng
fig
expect
among
differ
pi
test
saquinavir
nelfinavir
produc
strongest
inhibitori
effect
data
shown
next
doserespons
endocytosi
assay
use
differ
concentr
nelfinavir
carri
analyz
cellassoci
fluoresc
h
challeng
result
show
within
cell
challeng
wt
vsvg
nef
gfp
vlp
pi
treatment
reduc
mfi
percentag
fluoresc
cell
dosedepend
manner
highest
pi
concentr
paramet
reach
level
similar
detect
cell
challeng
fdvsvg
nef
gfp
vlp
fig
henc
seem
pi
treatment
divert
fate
endocytos
wt
vsvg
toward
fd
vsvg
vlp
strongli
suggest
pi
neg
affect
fusion
viral
envelop
endosom
membran
togeth
result
support
idea
inhibitori
effect
pi
act
level
deliveri
viral
particl
endosom
cytoplasm
infect
cell
possibl
explan
appar
block
viral
envelop
fusion
could
pi
may
increas
ph
endosom
way
inhibit
low
phdepend
conform
chang
need
vsvg
influenza
ha
switch
fusion
process
test
whether
pi
affect
intracellular
ph
hela
mdck
cell
label
lysosensor
green
reagent
becom
fluoresc
acid
intracellular
compart
meanwhil
exhibit
decreas
fluoresc
intens
upon
ph
increas
thu
repres
use
reagent
detect
possibl
ph
variat
endosom
cell
treat
overnight
pi
dose
effect
vsv
andor
influenza
viru
replic
label
lysosensor
green
min
presenc
pi
final
analyz
fac
control
cell
treat
bafilomycin
ie
power
inhibitor
vacuolar
atpas
proton
pump
also
test
depict
fig
signific
variat
cellassoci
fluoresc
detect
pitreat
cell
compar
control
condit
indic
pi
affect
intracellular
ph
result
strongli
suggest
piinduc
block
viru
deliveri
cytoplasm
would
consequ
increas
endosom
ph
virus
hijack
cell
function
replic
host
cell
henc
select
target
cell
product
support
viru
replic
could
repres
success
antivir
strategi
result
describ
investig
indic
drug
design
counteract
activ
hiv
proteas
show
strong
inhibitori
effect
activ
i
target
cell
antivir
potenc
effect
pi
reach
log
reduct
viru
yield
therapeut
index
higher
piinduc
effect
vsv
appear
compar
magnitud
observ
cell
treat
interferon
master
samuel
hand
potenc
pi
influenza
viru
replic
appear
compar
potent
inhibitor
among
furuta
et
al
reduc
viral
yield
suscept
influenza
strain
test
best
log
concentr
upon
mdck
cell
challeng
moi
sleeman
et
al
ie
sialidas
fusion
protein
block
influenza
viru
replic
submicromolar
concentr
howev
mdck
cell
challeng
moi
trianabaltz
et
al
convers
micromolar
concentr
pi
induc
log
reduct
influenza
viru
yield
mdck
cell
challeng
moi
challeng
experi
pi
ad
soon
adsorpt
vsv
influenza
viru
inocula
antivir
effect
appear
slightli
reduc
compar
control
condit
pi
maintain
throughout
consid
also
result
obtain
endocytosi
assay
conceiv
subtl
differ
could
consequ
access
cytoplasm
small
amount
viral
particl
adsorpt
time
pi
treatment
possibl
pi
affect
virion
structur
compon
way
hinder
process
fusion
endosom
appear
unlik
fact
treatment
concentr
vsv
influenza
viru
prepar
pi
min
challeng
produc
signific
decreas
viral
yield
shown
howev
formal
exclud
pi
inhibit
yet
unidentifi
proteas
activ
associ
vsvg
influenza
virion
regard
propos
pi
could
neg
affect
chymotrypsinlik
proteas
activ
pa
subunit
rnadirect
rna
polymeras
influenza
viru
savarino
furthermor
report
nelfinavir
reduc
replic
sar
coronaviru
yamamoto
et
al
like
consequ
inhibit
viral
proteas
review
see
result
report
experi
indic
pi
act
earli
event
viral
replic
viru
attach
endocytosi
latter
find
consist
previous
report
result
indic
pi
affect
endocytosi
particl
dendrit
cell
muratori
et
al
rather
appear
pi
interfer
deliveri
viral
particl
endosom
cytoplasm
seem
depend
piinduc
increas
endosom
ph
possibl
inhibit
low
phdepend
conform
chang
viral
envelop
protein
requir
viral
fusion
concept
activ
cell
proteas
part
mechan
underli
replic
mani
viru
speci
wide
accept
exampl
cleavag
ha
gener
cell
proteas
requir
activ
viral
envelop
protein
preced
viral
fusion
influenza
viru
klenk
et
al
lazarowitz
choppin
similarli
activ
envelop
protein
ebola
schornberg
et
al
nipah
pager
dutch
corona
virus
bosch
et
al
regul
cathepsin
ie
famili
cell
aspartylproteas
identif
host
factor
particular
aspartylproteas
involv
describ
piinduc
inhibit
viral
entri
deserv
investig
result
function
genet
screen
demonstr
altern
cell
proteas
act
cofactor
replic
differ
virus
clement
et
al
hao
et
al
krishnan
et
al
ng
et
al
nguyen
et
al
pelkman
et
al
concern
vsv
comparison
data
regard
cell
proteas
known
sensit
pi
identifi
proteasom
subunit
possibl
relev
pi
target
clement
et
al
appear
consist
recent
report
evid
ie
proteasom
inhibitor
inhibit
vsv
replic
neznanov
et
al
altern
function
genet
screen
reveal
also
could
part
mechan
vsv
replic
clement
et
al
consid
activ
like
mmp
might
affect
pi
would
interest
investig
role
mmp
describ
antivir
effect
pi
report
find
would
open
way
toward
preclin
assay
design
test
potenc
pi
vivo
infect
sustain
orthomyxoand
rabi
virus
also
interest
extend
investig
addit
pathogen
envelop
virus
infect
endocytosi
vsvg
pseudotyp
prepar
obtain
supernat
cell
h
cotransfect
cmv
immediateearli
promot
vsvgexpress
vector
vector
express
deriv
molar
ratio
perform
lipofectamin
method
invitrogen
supernat
clarifi
concentr
ultracentrifug
describ
federico
et
al
viru
prepar
titrat
measur
content
quantit
enzymelink
immunosorb
assay
elisa
innogenet
prepar
assay
vsv
indiana
strain
perform
basic
describ
gresser
et
al
briefli
high
titer
stock
vsv
prepar
upon
infect
hela
cell
low
multipl
infect
moi
ie
plaqu
form
unit
pfu
cell
supernat
harvest
h
later
clarifi
stock
frozen
vsv
titrat
high
titer
stock
carri
plaqu
method
apuerto
rico
pr
h
n
human
influenza
viru
grown
embryon
chicken
egg
allanto
fluid
clarifi
centrifug
min
viru
pellet
centrifug
h
resuspend
ml
phosphatebuff
salin
portion
solut
store
aliquot
influenza
prepar
titrat
standard
plaqu
assay
mdck
cell
viru
titer
stock
rang
pfuml
prepar
hertz
strain
ndv
recov
h
incub
embryon
chicken
egg
inocul
allanto
caviti
harvest
allanto
fluid
clarifi
centrifug
titrat
infecti
unitsml
enddilut
method
assess
cytopath
effect
mdck
cell
h
post
infect
titer
viral
stock
use
infecti
unitsml
cem
gfp
cell
grown
roswel
park
memori
institut
rpmi
medium
supplement
heatinactiv
fetal
calf
serum
fc
hela
mdck
induc
packag
cell
sparacio
et
al
grown
dulbecco
modifi
eagl
medium
plu
fc
infect
cem
gfp
cell
pseudotyp
deriv
carri
spinocul
g
min
room
temperatur
rt
use
ng
ng
equival
vsvg
cell
respect
viru
adsorpt
prolong
addit
h
final
cell
wash
refe
complet
medium
hela
cell
infect
vsv
adsorb
viral
inoculum
h
small
volum
eg
ml
serum
free
medium
cell
well
plate
thereaft
cell
extens
wash
refe
appropri
complet
medium
mdck
cell
use
target
influenza
viru
challeng
carri
vsv
infect
except
viru
adsorpt
cell
refe
medium
without
serum
presenc
tpcktreat
trypsin
worthington
biochem
corpor
hela
mdck
cell
serv
titrat
infecti
vsv
influenza
viru
supernat
harvest
challeng
experi
titrat
carri
enddilut
method
triplic
condit
challeng
cell
scale
supernat
dilut
presenc
tpcktrypsin
influenza
viru
titrat
evalu
cytopath
effect
h
vsv
h
influenza
viru
concentr
viru
prepar
previous
titrat
plaqu
assay
use
standard
ndv
infect
mdck
cell
challeng
decreas
viral
dilut
start
moi
cythopat
effect
assess
h
later
ritonavir
indinavir
saquinavir
nelfinavir
amprenavir
atazanavir
obtain
nih
aid
research
refer
reagent
program
control
pitreat
cell
label
cfse
molecular
probe
invitrogen
follow
manufactur
recommend
cell
sampl
immedi
process
determin
fluoresc
level
zero
time
thereaft
remaind
cell
cultur
refe
complet
medium
time
complet
one
cell
duplic
averag
h
hela
mdck
cell
logarithm
phase
harvest
fluoresc
measur
fac
analysi
dead
cell
identifi
upon
label
propidium
iodid
sigmaaldrich
prepar
fluoresc
vlp
challeng
detect
assay
fluoresc
vlp
obtain
previous
describ
muratori
et
al
briefli
packag
cell
cotransfect
vector
express
greenfluoresc
protein
gfp
fuse
nterminu
g
c
nef
mutant
togeth
vector
express
wt
fusiondefect
fd
vsvg
fredericksen
whitt
supernat
harvest
day
later
concentr
ultracentrifug
sucros
cushion
titrat
content
hela
cell
challeng
ng
equival
fluoresc
vsvg
cell
adsorb
h
volum
ml
well
plate
thereaft
ml
complet
medium
ad
final
cell
extens
wash
analyz
fac
endocytosi
assay
fac
analysi
carri
incub
trypsin
min
cell
purifi
vlp
prepar
lyse
pb
triton
presenc
antiproteolyt
agent
prepar
cytoplasm
extract
whole
cell
lysat
centrifug
min
supernat
frozen
aliquot
ng
equival
vlp
total
cell
protein
separ
sdspage
transfer
electroblot
nitrocellulos
membran
sartoriu
ag
min
v
biorad
transblot
nitrocellulos
membran
block
bovin
serum
albumin
bsa
fraction
v
sigma
ttbsedta
mm
trishcl
ph
mm
nacl
mm
edta
min
room
temperatur
incub
h
rt
specif
antibodi
dilut
bsa
ttbsedta
follow
ab
serv
revel
vlpand
cellassoci
product
arp
sheep
antinef
antiserum
mark
harri
univers
leed
leed
uk
rabbit
polyclon
antivsvg
ab
immunolog
consult
laboratori
monoclon
anti
human
amersham
pharmacia
biotech
immun
complex
detect
horseradish
peroxidaseconjug
goat
antisheep
antirabbit
calbiochem
antimous
ab
nen
follow
enhanc
chemioluminesc
reaction
euroclon
lysosensor
probe
molecular
probe
invitrogen
serv
detect
possibl
chang
endosom
ph
upon
pi
treatment
acidotrop
probe
accumul
acid
organel
exhibit
decreas
fluoresc
upon
ph
increas
cell
pretreat
pi
control
bafilomycin
sigmaaldrich
label
lysosensor
complet
medium
min
presenc
drug
afterward
cell
extens
wash
fix
fluoresc
evalu
fac
analysi
appropri
data
present
mean
standard
deviat
valu
sd
instanc
statist
analysi
perform
accord
pair
student
ttest
confirm
use
nonparametr
wilcoxon
rank
sum
test
pvalu
consid
signific
